Houston energy company exits, 3 recent investments from local fund, and more innovation news

Short stories

From a Houston startup exit to the growth of a Rice University startup, here's the short stories of Houston innovation news you may have missed. Pexels

Houston's innovation ecosystem has been booming with news, and it's likely some might have fallen through the cracks.

For this roundup of short stories within Houston innovation, Texas Halo Fund makes three new investments, a Houston energy company exits, a growing Rice University startup gets grants, and more.

Octopus Energy acquires Houston-founded Evolve Energy

The $5 million deal means a new focus on Texas for the new parent company. Photo via evolvemyenergy.com

London-based renewable energy company Octopus Energy announced that it's acquired Houston-founded Evolve Energy in a $5 million deal, which represents Octopus's $100 million expansion into the United States market.

Octopus, which reached Unicorn status with a $1 billion valuation in April, will start its expansion in Texas, according to a news release, operating under the new name Octopus Energy US. Evolve Energy, which was founded in 2018 by Michael Lee, is a Texas-based Capital Factory portfolio company and finished first place in the 2019 EarthX startup competition. The company also has a Silicon Valley office, in addition to its local operation in Houston's Galleria area.

"Octopus Energy is inspirational in growing a customer base of over 1 million households in just four years. It has done so while also achieving customer satisfaction scores similar to Netflix and Amazon. It matches our aspiration for innovation and we're thrilled to be part of the Octopus family," says Lee in the release. "The US energy market is rapidly moving towards ultra-low cost renewable energy and is prime for a true digital transformation."

Texas Halo Fund makes three new investments

Texas Money

Here are the three latest investments from Texas Halo Fund. Getty Images

Houston-based Texas Halo Fund has made three recent investments in August and September.

  • Nexus AI, based in Chicago, the workforce management tech company uses artificial intelligence and organizational behavioral science to predict the best teams or individuals for a project on the startup's cloud-based platform.
  • Rellevate is a Connecticut-based digital fintech company that optimizes employer-based digital account and financial services.
  • MFB Fertility, a Colorado company, has created game-changing at-home test stripts for assaying the hormone progesterone branded as Proov.

Rice University program seeking data projects

The Rice D2K Lab wants to help startups and small businesses solve business concerns with data science. Photo courtesy of Rice

Adata-focused lab at Rice University is seeking data challenges for its group of next generation of data scientists to solve. The Rice D2K Lab is looking for sponsors for its Rice D2K Capstone project in Spring 2021. Rice's D2K Capstone program forms interdisciplinary teams of advanced undergraduate and graduate students to solve pressing real-world data science challenges. The program is accepting project proposals for the Spring 2021 semester through Monday, October 19.

Click here to learn more about the program, and click here to get involved.

California startup joins Chevron's Catalyst Program

CTV has a new startup in its Catalyst Program. Photo via Getty Images

Houston-based Chevron Technology Ventures announced that Oakland, California-based Brimstone Energy Inc. has joined CTV's Catalyst Program to continue its development of its decarbonization platform, which focuses on the generation of low-emissions hydrogen, as well as various commodity products, according to a release.

"Brimstone Energy is excited to be supported by Chevron, a multi-national industrial company," says Cody Finke, Ph.D., co-founder and CEO of Brimstone Energy, in the release. "It is good to see Chevron continue to back companies with decarbonization in their mission."

Rice University-born startup racks up $12.5 million in grants

OpenStax is growing its access to free online textbooks. Image via openstax.org

Rice University's OpenStax is able to greatly expand its library of free online textbooks thanks to new grants totaling $12.5 million. The funds derive from Bill & Melinda Gates Foundation, the William and Flora Hewlett Foundation, the Charles Koch Foundation and the Stand Together community, according to a press release from Rice.

The new funds will more than double OpenStax's files from 42 books to 90. Already, the platform has saved 14 million students around the world more than $1 billion.

"Nine years ago, we dreamed about solving the textbook affordability and access crisis for students," says Richard Baraniuk, the Victor E. Cameron Professor of Electrical and Computer Engineering at Rice and founder and director of OpenStax, in the release. "Now, with this tremendous investment in open education, we will be able to not only accelerate educational access for tens of millions of students but also drive innovation in high-quality digital learning, which has become commonplace due to COVID-19."

OpenStax is planning to raise $30 million for continued library expansion as it aims to lower the barrier to higher education.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings